UNSPSC 51152067: Pancuronium bromide

This classification denotes a muscle relaxant with the molecular formula C35H60N2O4.2Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U9LY9Y75X2, chemically known as 5.alpha.-androstan-3.alpha.,17.beta.-diol, 2.beta., 16.beta.-dipipecolinio-, dibromide, diacetate but more generally known as pancuronium bromide, which bears US NIH Compound Identifier 4675. European Medicines Agency schedules Pancuronium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09603MIG.

UNSPSC 51152067 Pancuronium bromide is a Commodity code that nominally describes a neuromuscular blocking agent used in medical and surgical settings. However, recent state and local procurement activity tagged to this code shows little connection to pancuronium bromide itself. The most recent opportunities instead involve naloxone procurement and pharmaceutical benefit management strategy—neither of which aligns with the code's stated scope. State and local governments do solicit pharmaceutical products and medical supplies through UNSPSC coding, but the two recorded opportunities under this code appear to be misclassified or represent a mismatch between the code assignment and actual procurement need.

The Seminole County, Florida Procurement Department issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted Request for Information HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, designed to inform future state procurement strategy around pharmacy benefit management and direct contracting with manufacturers—a market-intelligence phase with no immediate award or budget. Neither opportunity substantively addresses pancuronium bromide procurement. Given the low relevance of recent postings to the code's nominal scope, businesses evaluating this code should confirm accurate UNSPSC classification with individual issuing bodies before pursuing opportunities, as the current activity signals either persistent miscoding or minimal genuine demand for this specific pharmaceutical commodity at the state and local level.